Hoffman Robert E. 4

What Happened Robert E. Hoffman, a director of FibroBiologics, was granted a derivative award representing 30,803 shares on June 23, 2026. The reported acquisition price is $0.00, so no cash was paid. The filing classifies this as a grant/award (derivative securities) rather than an open-market purchase or sale—typical of compensation or board awards.

Key Details

• Transaction date: 2026-06-23; Filing date: 2026-06-23 (timely).
• Reported amount: 30,803 derivative shares; reported price: $0.00; reported total value: $0 (per filing).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: The award will vest in full upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting.
• Transaction code: A (Grant, award or other acquisition); this is a compensation/award event, not a market buy or sale.

Context This is an awards-based (derivative) grant commonly used for director compensation; it does not indicate an immediate market purchase or sale. The vesting condition means Hoffman must wait up to a year (or until the next annual meeting) before the award becomes fully vested. As reported, no cash changed hands at grant.